跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 11 天前AI 评分57

ImmunityBio称ANKTIVA联合BCG在QUILT-2.005试验Cohort A达到主要终点

ImmunityBio, Inc. (0001326110) (Filer)

AI 导读

ImmunityBio于2026年11月9日发布公告称,ANKTIVA联合卡介苗(BCG)在针对未接受过BCG治疗的非肌层浸润性膀胱癌患者的随机QUILT-2.005试验Cohort A中达到主要终点。相关信息通过公司8-K第7.01项披露,完整新闻稿作为附件99.1提供。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2026

ImmunityBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware001-3750743-1979754

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3530 John Hopkins Court

San Diego, California 92121

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (844) 696-5235

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per shareIBRXThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 7.01    Regulation FD Disclosure.

On November 9, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that ANKTIVA® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto.

The information pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filings of the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language of such filing, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

Exhibit
Number
Description of Exhibit
  99.1**

Press release dated November 9, 2026.

  104Cover Page Interactive Data File (embedded within the Inline XBRL document).

_______________

**    Furnished herewith.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNITYBIO, INC.
Registrant

Date: November 9, 2026

By:/s/ David C. Sachs
David C. Sachs
Chief Financial Officer

来源:SEC EDGAR · 本站存档